Literature DB >> 19016106

Evaluation of the tolerance and distribution of intravenously applied ferrofluid particles of 250 and 500 nm size in an animal model.

Susanne Wiegand1, Thomas Heinen, Annette Ramaswamy, Andreas M Sesterhenn, Christian Bergemann, Jochen A Werner, Andreas S Lübbe.   

Abstract

OBJECTIVE: Magnetic drug targeting may be a new method for the treatment of malignant tumors. According to the previous investigations, the success of magnetic targeting is generally contingent upon the magnetic properties and size distribution of the magnetic nanoparticles. Therefore, the aim of the present study was to verify the tolerance of two ferrofluid dispersions modified in particle size and density.
MATERIALS AND METHODS: 8.75 ml ferrofluid with particle sizes of 250 or 500 nm were applied intravenously to two groups of seven New Zealand White rabbits in three doses in a time frame of 2 h. Clinical, serological,and histological evaluations were performed with regard to the tolerance of the ferrofluids.
RESULTS: All animals tolerated the ferrofluid application without any clinical irregularities; there were no signs of thrombosis or embolism. Histological analysis revealed an accumulation in the liver, spleen, lung, and kidney depending on the particle size; the serological examination did not show significant alterations of the blood parameters.
CONCLUSION: The ferrofluids of 250 and 500 nm particle sizes were well tolerated as shown by the laboratory and histological data and should be evaluated in further studies regarding their clinical use in magnetic drug targeting.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19016106     DOI: 10.1080/10611860802582467

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  5 in total

1.  Tracking of multimodal therapeutic nanocomplexes targeting breast cancer in vivo.

Authors:  Rizia Bardhan; Wenxue Chen; Marc Bartels; Carlos Perez-Torres; Maria F Botero; Robin Ward McAninch; Alejandro Contreras; Rachel Schiff; Robia G Pautler; Naomi J Halas; Amit Joshi
Journal:  Nano Lett       Date:  2010-11-22       Impact factor: 11.189

2.  Multimodal Multiplexed Immunoimaging with Nanostars to Detect Multiple Immunomarkers and Monitor Response to Immunotherapies.

Authors:  Yu-Chuan Ou; Xiaona Wen; Christopher A Johnson; Daniel Shae; Oscar D Ayala; Joseph A Webb; Eugene C Lin; Rossane C DeLapp; Kelli L Boyd; Ann Richmond; Anita Mahadevan-Jansen; Marjan Rafat; John T Wilson; Justin M Balko; Mohammed N Tantawy; Anna E Vilgelm; Rizia Bardhan
Journal:  ACS Nano       Date:  2020-01-02       Impact factor: 15.881

3.  Synergistic targeting of cell membrane, cytoplasm, and nucleus of cancer cells using rod-shaped nanoparticles.

Authors:  Sutapa Barua; Samir Mitragotri
Journal:  ACS Nano       Date:  2013-09-27       Impact factor: 15.881

4.  A/C magnetic hyperthermia of melanoma mediated by iron(0)/iron oxide core/shell magnetic nanoparticles: a mouse study.

Authors:  Sivasai Balivada; Raja Shekar Rachakatla; Hongwang Wang; Thilani N Samarakoon; Raj Kumar Dani; Marla Pyle; Franklin O Kroh; Brandon Walker; Xiaoxuan Leaym; Olga B Koper; Masaaki Tamura; Viktor Chikan; Stefan H Bossmann; Deryl L Troyer
Journal:  BMC Cancer       Date:  2010-03-30       Impact factor: 4.430

5.  Urokinase-coated chitosan nanoparticles for thrombolytic therapy: preparation and pharmacodynamics in vivo.

Authors:  Hai-jiang Jin; Hao Zhang; Min-li Sun; Bai-gen Zhang; Ji-wei Zhang
Journal:  J Thromb Thrombolysis       Date:  2013-11       Impact factor: 2.300

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.